Meridian Bioscience, Inc.  

(Public, NASDAQ:VIVO)   Watch this stock  
Find more results for VIVO
0.00 (0.00%)
Aug 18 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 10.75 - 19.85
Open     -
Vol / Avg. 0.00/222,607.00
Mkt cap 576.07M
P/E 27.22
Div/yield 0.12/3.66
EPS 0.50
Shares 42.20M
Beta 0.88
Inst. own 92%
Nov 8, 2017
Q4 2017 Meridian Bioscience Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Aug 10, 2017
Meridian Bioscience Inc at Canaccord Genuity Growth Conference
Jul 27, 2017
Q3 2017 Meridian Bioscience Inc Earnings Release
Jun 7, 2017
Meridian Bioscience Inc at Jefferies Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin 0.48% 16.44%
Operating margin 8.58% 26.20%
EBITD margin - 30.68%
Return on average assets 0.39% 14.81%
Return on average equity 0.57% 19.39%
Employees 650 -
CDP Score - -


3471 River Hills Dr
United States - Map
+1-513-2713700 (Phone)
+1-513-2713762 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Meridian Bioscience, Inc. is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers. Its segments include Diagnostics and Life Science. The Diagnostics segment includes manufacturing operations in Cincinnati, and the sale and distribution of diagnostic test kits in the countries consisting of North, Central and South America; Europe, the Middle East and Africa (EMEA), and other countries outside of the Americas and EMEA. The Life Science segment consists of manufacturing operations in Memphis, Tennessee; Boca Raton, Florida; London, England; Luckenwalde, Germany, and Sydney, Australia.

Officers and directors

John A. Kraeutler Chairman of the Board, President, Chief Executive Officer
Age: 68
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Lawrence J. Baldini Executive Vice President and President, Global Operations
Age: 56
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Richard L. Eberly Executive Vice President, President, Chief Commercial Officer
Age: 54
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Melissa A. Lueke Chief Financial Officer, Executive Vice President, Secretary
Age: 52
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Marco G. Calzavara President and Managing Director of Meridian Bioscience Europe
Age: 61
Bio & Compensation  - Reuters
Vecheslav A. Elagin Ph.D. Executive Vice President - Research and Development
Age: 48
Bio & Compensation  - Reuters
Susan D. Rolih Executive Vice President - Regulatory & Quality Systems
Age: 66
Bio & Compensation  - Reuters
David C. Phillips Lead Independent Director
Age: 78
Bio & Compensation  - Reuters
James M. Anderson Independent Director
Age: 74
Bio & Compensation  - Reuters
Dwight E. Ellingwood Independent Director
Age: 64
Bio & Compensation  - Reuters